Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model

Fig. 4

Immunohistochemistry staining for assessment of human bone marrow-derived mesenchymal stem cell (BM-MSC) and umbilical cord-derived mesenchymal stem cell (UC-MSC) survival. Host cells are stained by 4',6-diamidino-2-phenylindole (DAPI). Mouse monoclonal antibody against human nuclei positive cells (transplanted cells) continue to survive in the spinal cord after 8 weeks (n = 3 in each group). The survival rates were 0.36 ± 0.06 % and 0.57 ± 0.06 % in BM-MSC and UC-MSC groups, respectively (p = 0.002)

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512